Select region:

Clinical trials located in

Regensburg

Regensburg city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Regensburg, a UNESCO World Heritage Site, is one of Germany’s oldest cities, tracing its history back to Roman times. Situated at the confluence of the Danube, Naab, and Regen rivers, it boasts a well-preserved medieval old town. The city is renowned for its architectural landmarks, including the 12th-century Stone Bridge and the Gothic St. Peter’s Cathedral. Regensburg was a major center during the Holy Roman Empire and retains a rich cultural heritage, with ancient structures that reflect its storied past.

  • CT-EU-00112349

    Testing New Therapies for Glioblastoma Brain Cancer

    Howdy there, partner! This here trial is called the GBM AGILE study, and it’s aiming to find better treatments for a type of brain cancer called glioblastoma. Now, glioblastoma is a real tough customer, but this study is taking a new approach by testing multiple therapies all at once, both for newly diagnosed cases and for those where the cancer has come back.

    The main goal is to find treatments that work better and can be matched to different types of glioblastoma. The study uses a fancy method called Bayesian response adaptive randomization to assign folks to different treatment arms based on how well those treatments are performing. The most important measure they’re looking at is overall survival – how long patients live after starting treatment.

    Some of the therapies being tested include drugs like temozolomide, lomustine, regorafenib, paxalisib, VAL-083, VT1021, and troriluzole. These come in different forms like capsules, tablets, or infusions, and the dosages and schedules vary depending on the drug. The study is set up so that new promising therapies can be added in, and ones that aren’t working so well can be removed as the trial goes on.

    FranceGermany
  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    AustriaBelgiumFinlandFranceGermanyHungaryItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Exploring treatment options for newly diagnosed Multiple Myeloma

    This clinical trial investigates two treatment paths for newly diagnosed multiple myeloma patients who are not planned for stem cell transplant initially. The first group receives a combination of bortezomib, lenalidomide, and dexamethasone (VRd) followed by cilta-cel, an innovative therapy. The second group receives VRd followed by continued treatment with lenalidomide and dexamethasone (Rd). The study evaluates the effectiveness of these treatments by monitoring disease progression, treatment response, and patient survival rates. It also assesses the safety and side effects of the treatments, aiming to improve the quality of life and outcomes for patients with multiple myeloma. The trial’s objective is to provide valuable data on the potential benefits of integrating cilta-cel in the treatment regimen, compared to the more traditional approach, offering insights for better management of this challenging cancer.

    AustriaBelgiumCzechiaDenmarkFinlandFranceGermanyGreeceHungaryNetherlandsNorwayPolandSwedenUnited Kingdom
  • Evaluating the efficacy of macitentan in the treatment of high pulmonary artery blood pressure

    This study is checking if a 75 mg dose of a medicine called Macitentan can do a better job for patients with a lung condition called Pulmonary Arterial Hypertension (PAH) compared to a 10 mg dose. The main goal is to see if the 75 mg dose can better delay the patient’s first major health event related to PAH. Major events include things like unplanned hospital stays related to PAH, or their PAH getting worse. The researchers will check if patients’ PAH gets worse by looking at things like their physical exercise ability and signs of heart failure. The study also looks at how patients’ symptoms change from day to day.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSlovakiaSpainSwedenUnited Kingdom
  • Sotatercept treatment study for new Pulmonary Hypertension patients

    This study is an important test where doctors are looking at how a drug called Sotatercept can help people struggling with Pulmonary Arterial Hypertension (or PAH for short). The goal is to see whether this drug can delay or prevent the condition from getting worse. PAH makes it really hard for patients to breathe because it affects lungs and heart. The testing process is being done in a fair and careful way. Half of the patients will get the drug, and the others will get a ‘placebo’ which doesnt contain any medicine. The doctors will look at the effect on patients over time. The study is looking specifically at patients who were recently diagnosed with PAH and are at risk for the disease to get worse.

    AustriaBelgiumCzechiaDenmarkFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Use of tucatinib in combination therapy for HER2-positive breast cancer

    This study examines whether tucatinib, combined with other medications, is more effective than a placebo in treating HER2-positive breast cancer. The research will also identify any side effects from the drug combination. Participants in this study have advanced breast cancer that is either unresectable (cannot be surgically removed) or metastatic (spread throughout the body). Participants will be randomly assigned to receive either tucatinib or a placebo, without knowing which one they are receiving. This method ensures the study’s fairness and accuracy. Additionally, all participants will receive trastuzumab and pertuzumab, two drugs effective against this cancer type. These will be administered every 21 days, either intravenously or subcutaneously, depending on the specific drug and combination used. The study has two main groups: one receiving a placebo and the other tucatinib, both alongside trastuzumab and pertuzumab.

    AustriaBelgiumCzechiaFinlandFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • R-Pola-Glo therapy for aggressive B-cell lymphoma

    This clinical study tests a new treatment combination called R-Pola-Glo for elderly or medically unfit patients with untreated aggressive B-cell lymphoma. It involves the anti-CD20 antibody rituximab with polatuzumab vedotin and glofitamab, aiming to develop a less intense chemotherapy option. The trial, enrolling 80 participants, will assess the effectiveness and safety of this therapy, which could be crucial for those ineligible for standard treatment due to age or health.

    AustriaGermany
  • Study of lacutamab in T-cell lymphoma

    This trial involves a medication called lacutamab, which will be given to patients who have a type of blood cancer known as peripheral T-cell lymphoma, and their disease has either come back after previous treatment or didn’t respond at all. Some patients in the study will receive lacutamab in combination with a common chemotherapy drugs gemcitabine and oxaliplatine, while others will get only gemcitabine and oxaliplatine. A key aim of this study is to find out if lacutamab is both safe and effective. The study is designed not to compare the two treatments directly, but to check our assumptions for deciding the number of people for the trial. The number of participants getting lacutamab is bigger.

    BelgiumFranceGermanySpain
  • Study of nivolumab + relatlimab for new advanced melanoma cases

    The study explores the effects of combining Nivolumab and Relatlimab, given subcutaneously, in treating melanoma that hasn’t been treated before and can’t be surgically removed. The focus is on the medication levels in the blood and comparing the treatment’s impact on the disease with standard methods​​.

    AustriaBelgiumCzechiaFinlandFranceGermanyItalyNorwayPolandSpainSwedenUnited Kingdom
  • Testing ustekinumab treatment for severe ulcerative colitis

    This clinical trial is focused on understanding the safety and effectiveness of a medication named Ustekinumab in children and adolescents who are experiencing moderate to severe Ulcerative Colitis (UC), a type of inflammatory bowel disease that causes long-lasting inflammation and ulcers in the digestive tract. The study administers Ustekinumab initially through an IV (intravenous infusion) and then as a subcutaneous injection. The main aims are to determine whether Ustekinumab can help these young patients achieve clinical remission, meaning their UC symptoms are reduced or completely go away, and to monitor how the drug behaves in their bodies. Throughout the trial, the health and safety of the participants are closely monitored.

    BelgiumGermanyHungaryPolandUnited Kingdom
  • Testing mavacamten for heart muscle disease

    This study aims to assess a drug called Mavacamten for a heart condition called Non-Obstructive Hypertrophic Cardiomyopathy. Patients will be randomly given either the actual drug or a placebo without anyone knowing which one they’ve received. The study will measure how safe and effective the drug is for patients with symptoms of this heart condition. The success of the drug will be determined by preventing heart-related issues such as heart attacks, strokes, heart failures, irregular heartbeats, and the need for a heart-rhythm controlling device.

    AustriaBelgiumCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsNorwayPolandPortugalSpainUnited Kingdom
  • Examining midostaurin and chemotherapy for new child leukemia patients

    This research study is checking out a medication named Midostaurin. It is aimed at kids who have a certain type of blood cancer (FLT3-mutated Acute Myeloid Leukemia). The drug will be combined with the standard chemotherapy treatment. The researchers will look at how safe this combination is and how well it works. At the same time, they’ll examine how the body absorbs and gets rid of the medication. The study will have two parts. The first one is to figure out the best dosage, and the second one is to confirm how safe and effective it is. Both phases include 2 stages of chemotherapy to defeat the disease, 3 steps of follow-up chemo to make sure the disease doesn’t return, and a year-long treatment with Midostaurin on its own. If at any phase of the treatment, the disease comes back, the therapy will be stopped.

    AustriaCzechiaGermanyItalyPolandSlovenia
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Examining new treatment for digestive complications of Graft Versus Host Disease

    This study is examining the effects of a therapy called MaaT013 in patients who do not respond well to a drug called Ruxolitinib. Patients suffer from a disease called acute GVHD that affects their stomach. Previous studies have shown promising results, with most patients showing improvement after receiving MaaT013. Due to these results, MaaT013 will be used as “rescue therapy” in patients who do not improve with steroids or JAK inhibitors, drugs often used to treat the disease. The standard first treatment for acute GVHD is steroids, but some patients do not respond well to this treatment, and those who do may have serious side effects if they take high doses for a long time. Therefore, scientists are interested in exploring alternative treatments such as MaaT013. A drug called Ruxolitinib was approved by the FDA in 2019, but again, not all patients respond well to this treatment, prompting the need to develop alternatives.

    AustriaBelgiumFranceGermanyItalySpain
  • Testing ranibizumab for neovascular age-related macular degeneration

    This study, called Velodrome, is looking into a new treatment method for a condition affecting the eyes called ‘Neovascular Age-Related Macular Degeneration’. The treatment uses a technique called the Port Delivery System, along with a drug called ranibizumab. The aim of the study is to see how safe and effective this treatment is over a period of 36 weeks, compared to a period of 24 weeks. This study is important because it might mean people with this condition might have to have fewer treatments, and potentially see better.

    AustriaBelgiumFranceGermanyItalySpainUnited Kingdom
  • Combination therapy trial for moderately to severely active Crohn’s disease

    The study examines a combination therapy using guselkumab and golimumab in individuals with active Crohn’s Disease. It aims to compare the effectiveness of this dual approach to individual treatments, focusing on reducing disease symptoms and improving patients’ quality of life. The study’s goal is to offer new hope and better management strategies for those battling this challenging condition.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalSloveniaSpainSwedenUnited Kingdom
  • Comparison of new treatment and standard care for lymphoma patients

    A new approach to treating Lymphoma, a type of cancer originating in cells constituting the body’s immune system, is being tested in this trial. Comparison is being made between a new treatment, referred to as MB-CART2019.1, and the presently conventional treatment. The MB-CART2019.1 therapy is designed to target the aberrant B cells responsible for this form of cancer. In the process of creating MB-CART2019.1, cells are extracted from the patient’s own body, modified in the laboratory to combat cancer, and subsequently reintroduced into the patient. Participants in this trial will receive either MB-CART2019.1 or the standard treatment. The standard treatment involves the use of a drug combination (rituximab, gemcitabine, oxaliplatin (R-GemOx) or bendamustine, rituximab (BR) + polatuzumab vedotin). The objective is to assess whether MB-CART2019.1 demonstrates superior efficacy compared to these conventional drugs. Patient progress will be closely monitored for approximately one year to evaluate their well-being.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandSpainSweden
  • Apalutamide treatment for advanced prostate cancer post-surgery

    This clinical trial is looking into a treatment that could help people with a high risk of prostate cancer that could spread to other body parts after surgery. The treatment being studied is called apalutamide. The researchers want to see if this apalutamide can help stop the cancer from returning and spreading after surgery, compared to the standard care that these patients get. The trial will measure the amount of time until the cancer comes back, it has spread to other parts, or a patient dies from any cause. If there’s an increase in PSA (it is a protein made by normal cells and prostate cancer cells), the disease might have come back. The trial will also look at whether and how fast the PSA levels increase after recurrence. If there are no such events until the end of the observation period, the patient’s observation will end on the date of their last contact. The trial also looks at how safe this treatment is and what side effects it may cause.

    AustriaGermany
  • Study testing new chemotherapy combination for aggressive B-Cell Lymphoma treatment

    This study is for people over 60 who have never been treated for an aggressive type of blood cancer, called B-cell lymphoma, and who can’t receive the regular treatment, called R-CHOP. Instead of traditional chemotherapy, researchers will use the light treatment concept R-Pola-Glo that combines the anti-CD20 antibody rituximab (R) with the ADC polatuzumab vedotin (Pola) and the (BiMabs) glofitamab (Glo). The trial will look at factors like how long it takes for the disease to come back or get worse, the response rates after 2, 6, and 12 treatment cycles, and the percentage of people who experience side effects. It will also consider the effect on life quality, using two surveys designed by cancer research organizations.

    AustriaGermany

See more clinical trials in other cities in Germany:

.